Work

Abstract A94: Dose determination of LY2603618, a Chk1 inhibitor, administered in combination with gemcitabine in patients with advanced cancer.

Year: 2011

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-11-a94

Authors: Emiliano Calvo, Donald Richards, Fadi Braiteh, Daniel Von Hoff, Robert McWilliams, Carlos Becerra, Matthew Galsky, Gayle Jameson, Karla C. Hurt, Scott Hynes, Ignacio Garcia-Ribas, Aimee Bence, Eric Westin

Institutions: Hospital Universitario HM Sanchinarro, University of California, Los Angeles, Comprehensive Cancer Centers of Nevada, Translational Genomics Research Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Eli Lilly (United States)

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2067188144

Cites:

Cited by: 2

Related to: 10